Study types of pancreatic cancer using tumor gene testing
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies metastatic pancreatic cancer by taking a small tissue sample and analyzing its genes. It may help doctors better understand which cancer subtypes patients have, which can guide future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread (metastatic PDAC), confirmed by scan and/or biopsy
- You are starting first-line (initial) treatment with FOLFIRINOX or gemcitabine plus a similar drug (GP), possibly as part of a study
- You are age 18 or older and can give informed consent
- Your overall health is good enough for treatment (ECOG score 0–1) and you’re expected to live more than 90 days
- You have measurable cancer on imaging and a biopsy site that a doctor can safely reach with a needle
- You can lie flat for more than 60 minutes, and your organs are working well enough for the planned treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
This study follows how pancreatic cancer changes over time while you’re receiving treatment before surgery. It may help doctors understand how the cancer evolves and guide better future treatment choices.
This study looks at MRI scans, computer-extracted imaging features, and blood/“liquid biopsy” tests after FOLFIRINOX chemotherapy to predict whether surgery can fully remove pancreatic cancer. It may help your care team choose the best next step—whether surgery is likely to be possible and how to plan it.
This study looks at advanced or metastatic pancreatic cancer patients and uses stored tumor tissue to learn what may predict treatment outcomes. You may be able to join if you have had limited prior chemotherapy and can provide an archived tissue sample.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial tests a method that analyzes your tumor's genes and grows a mini-tumor in a dish to find which drugs might work best for your metastatic pancreatic cancer. It aims to improve treatment choices by using these personalized tests.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.